^
    Back
    Association details:
    Biomarker:HRD
    Cancer:Triple Negative Breast Cancer
    Drug:carboplatin (Tubulin polymerization promoter) +
    paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) +
    Myocet (non-pegylated liposomal doxorubicin) (Topoisomerase II inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

    Published date:
    09/11/2021
    Excerpt:
    Functional HRD was pre-defined as a RAD51 score ≤10% (RAD51-low). Patients with RAD51-low tumors benefited from PMCb (pCR 66% vs 33%, OR 3.96, 1.56-10.05, p=0.004; interaction test p=0.02).
    DOI:
    10.1016/j.annonc.2021.09.003